PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9406969-4	1997	All the responses to DVN injections of AII were totally prevented by DVN injection of 1 nmol of losartan, a mammalian non-peptide AII subtype 1 (AT1) receptor antagonist.	Losartan	96-104	NLR family pyrin domain containing 3	Homo sapiens	39-42	
9406969-4	1997	All the responses to DVN injections of AII were totally prevented by DVN injection of 1 nmol of losartan, a mammalian non-peptide AII subtype 1 (AT1) receptor antagonist.	Losartan	96-104	NLR family pyrin domain containing 3	Homo sapiens	130-133	
8172070-6	1994	The discovery of simple benzyl-substituted imidazoles, which possess weak but highly selective A-II receptor antagonistic properties, led to the development of losartan (DuP 753).	Losartan	160-168	NLR family pyrin domain containing 3	Homo sapiens	95-99	
8172070-6	1994	The discovery of simple benzyl-substituted imidazoles, which possess weak but highly selective A-II receptor antagonistic properties, led to the development of losartan (DuP 753).	Losartan	170-177	NLR family pyrin domain containing 3	Homo sapiens	95-99	
8172070-7	1994	Losartan is a potent, orally active, specific, competitive nonpeptide A-II receptor antagonist that appears to be an effective antihypertensive agent both in animal studies and in preliminary clinical trials.	Losartan	0-8	NLR family pyrin domain containing 3	Homo sapiens	70-74	
8172070-10	1994	Furthermore, losartan, a selective A-II type 1 (AT1) receptor antagonist, has also been a valuable pharmacologic probe for studying the mechanism of A-II stimulation of its receptors.	Losartan	13-21	NLR family pyrin domain containing 3	Homo sapiens	35-39	
8172070-10	1994	Furthermore, losartan, a selective A-II type 1 (AT1) receptor antagonist, has also been a valuable pharmacologic probe for studying the mechanism of A-II stimulation of its receptors.	Losartan	13-21	NLR family pyrin domain containing 3	Homo sapiens	149-153	
15629544-6	2005	Losartan infused into the portal vein abolishes PHR to AII but not the metabolic response; when infused via both pathways it abolishes the hypertensive responses and inhibits the metabolic effects.	Losartan	0-8	NLR family pyrin domain containing 3	Homo sapiens	55-58	
15629544-11	2005	Hemodynamic responses to AII are losartan-dependent but metabolic responses are partially losartan-independent.	Losartan	33-41	NLR family pyrin domain containing 3	Homo sapiens	25-28	
12034692-13	2002	Losartan (1 microM) significantly blocked the AII induced BK channel activation (p=0.0131), the Ca(2+)(I) response (p<10(-4)), and the AII induced volume effect (p=0.0046).	Losartan	0-8	NLR family pyrin domain containing 3	Homo sapiens	46-49	
15025837-0	2004	AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan.	Losartan	83-91	NLR family pyrin domain containing 3	Homo sapiens	0-3	
12034692-13	2002	Losartan (1 microM) significantly blocked the AII induced BK channel activation (p=0.0131), the Ca(2+)(I) response (p<10(-4)), and the AII induced volume effect (p=0.0046).	Losartan	0-8	NLR family pyrin domain containing 3	Homo sapiens	138-141	
11026543-3	2000	The conformations of compounds with a good binding activity are quite similar to that of DuP753, a prototype of AII antagonist, suggesting that these compounds also bind to the same site of AII receptor.	Losartan	89-95	NLR family pyrin domain containing 3	Homo sapiens	112-115	
11026543-3	2000	The conformations of compounds with a good binding activity are quite similar to that of DuP753, a prototype of AII antagonist, suggesting that these compounds also bind to the same site of AII receptor.	Losartan	89-95	NLR family pyrin domain containing 3	Homo sapiens	190-193	
10971280-9	2000	Responses to AII in strips from children under 3 years old were antagonized by the AT1 receptor antagonist losartan (1 micromol/L) but not by the AT2 receptor antagonist PD 123319 (1 micromol/L), indicating interaction with the AT1 receptor.	Losartan	107-115	NLR family pyrin domain containing 3	Homo sapiens	13-16